Donate by 12/31
Research Grants - 2011


Alzheimer's Assocation Research only
All of alz.org
  • Go to Alz.org
  • Research Center
  • AAIC
  • ISTAART
  • Journal
  • Grants
  • TrialMatch
  • Press
  • Donate
  • Contact Us
Home
Science and Progress
Clinical Trials
Funding and Collaboration
You can Help
Stay Current
Video and Resources

Text Size

Small text Medium text Large text

Research Grants 2011


To view an abstract, select an author from the vertical list on the left.

2011 Grants - Landreth

Mechanisms of RXR-Stimulated Reversal of Amyloid-Induced Phenotypes

Gary Landreth, Ph.D.
Case Western Reserve University
Cleveland, Ohio

2011 Zenith Fellows Award

Retinoid X receptor (RXR) is a protein in cells that controls the expression of other proteins by regulating cellular genes. One of the genes regulated by RXR is the ApoE gene. This regulation is important because defects in the ApoE protein are known to be a strong risk factor for Alzheimer's disease; thus, regulation of ApoE expression may also influence the risk for disease.

Gary Landreth, Ph.D., and colleagues have been studying how activation of RXR affects the development of Alzheimer's-like pathology. For these studies, they use mice that have been genetically altered to express high levels of beta-amyloid, a protein fragment that aggregates to form amyloid plaques, one of the hallmarks of Alzheimer's pathology. Dr. Landreth's research team found that bexarotene, a drug that activates RXR, rapidly reduces brain beta-amyloid levels in mice when given orally. After treatment, the mice also exhibit improvements in learning and memory. The researchers have proposed to study how bexarotene improves clearance of beta-amyloid from the brain, focusing on the role of ApoE because this protein is known to be involved in this process. They also plan to study how other cells in the brain, known as microglia and phagocytes, participate in the clearance of beta-amyloid. These studies will advance knowledge of how beta-amyloid is cleared from the brain and whether activation of the RXR protein may be a potential target for drugs to treat Alzheimer's disease.